BioCentury
ARTICLE | Clinical News

Abraxane meets endpoint in first-line metastatic melanoma

October 3, 2012 12:27 AM UTC

Celgene Corp. (NASDAQ:CELG) said Abraxane nab-paclitaxel met the primary endpoint of progression-free survival (PFS) vs. dacarbazine in the Phase III CA033 trial in 529 chemotherapy-naive patients wit...